Latest Articles

Publication Date
Dysfunction of natural killer cells promotes immune escape and disease progression in endometriosis.

Endometriosis (EMs) is a chronic inflammatory disorder characterized by dysregulated innate immunity, particularly impaired cytotoxic function of natural killer (NK) cells. As pivotal effectors of the innate immune response, NK …

Published: Sept. 5, 2025, midnight
Emerging Mechanisms of NK Cell Dysfunction in Endometriosis: The Role of Autophagy, Metabolism, Cytokines, Exosomes, and Trogocytosis.

Endometriosis (EMS) is a persistent, inflammatory condition that relies on estrogen and is distinguished by the proliferation of endometrial tissue outside the confines of the uterus. The impact on the …

Published: Aug. 27, 2025, 12:01 a.m.
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com

GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com

Published: Aug. 26, 2025, 4:39 a.m.
Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation - Frontiers

Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation Frontiers

Published: Aug. 25, 2025, 10:47 a.m.
TET3 is a common epigenetic immunomodulator of pathogenic macrophages.

Through a combination of single-cell/single-nucleus RNA-sequencing (sc/snRNA-seq) data analysis, immunohistochemistry, and primary macrophage studies, we have identified pathogenic macrophages characterized by TET3 overexpression (Toe-Macs) in three major human diseases associated …

Published: Aug. 12, 2025, midnight
Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal

Immunotherapy plus chemotherapy approved for endometrial cancer The Pharmaceutical Journal

Published: Aug. 7, 2025, 2:48 p.m.
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive

Published: Aug. 7, 2025, 8:48 a.m.
NICE approves first immunotherapy combination for endometrial cancer - Wired Gov

NICE approves first immunotherapy combination for endometrial cancer Wired Gov

Published: Aug. 6, 2025, 1:13 p.m.
First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central

First immunotherapy combination for endometrial cancer approved by NICE Oncology Central

Published: Aug. 6, 2025, 11:18 a.m.
First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government

First immunotherapy for advanced endometrial cancer approved in the UK Open Access Government

Published: Aug. 6, 2025, 8:50 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!